Drugs / Vaxigrip
Vaxigrip
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00386542 | Oct 2006 → Nov 2009 | influenza | Pedro Moro | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03016143 | Oct → Nov 2016 | influenza | Research Institute for Biological Safety Problems | Completed | No outcome recorded |
| Phase 2 | NCT00776438 | Sep 2007 → Feb 2009 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01249183 | Oct 2010 → Sep 2011 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01022749 | Sep 2009 → Jul 2011 | inflammatory bowel disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06286488 | Sep 2020 → Aug 2023 | influenza, obesity disorder | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 4 | NCT02957890 | Nov 2016 → Sep 2025 overdue | influenza | The University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02640989 | Oct 2014 | influenza | Center for Disease Prevention and Control of Beijing Military Region | Completed | No outcome recorded |
| Phase 4 | NCT03266237 | Dec 2013 → May 2016 | influenza | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT01665807 | Sep → Dec 2012 | influenza | Brenda Coleman | Completed | No outcome recorded |
| Phase 4 | NCT01000584 | Nov 2009 → Feb 2010 | swine influenza | David Scheifele | Completed | No outcome recorded |
| Phase 4 | NCT01119157 | Nov 2008 → Mar 2009 | — | National Centre for Epidemiology, Hungary | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01916759 | Jun → Dec 2013 | AIDS, influenza | Emory University | Completed | No outcome recorded |
| — | NCT01180699 | Oct 2010 → Aug 2012 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT00758212 | Nov 2008 → Jan 2009 | AIDS, influenza | Hadassah Medical Organization | Unknown | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1 | NCT02645032 Comparator | May 2016 → Feb 2017 | typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01707602 Comparator | Oct → Dec 2012 | influenza | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT01010737 Background | Sep 2009 → Mar 2010 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00778895 Comparator | Nov 2008 → Aug 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT07604103 Comparator | Jan → Aug 2026 overdue | acute coronary syndrome, chronic obstructive pulmonary disease, pneumonia | University of Brawijaya | Recruiting | No outcome recorded |
| Phase 3 | NCT05470582 Comparator | Feb → Oct 2021 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Phase 3 | NCT02263131 Comparator | Oct 2013 → Jan 2014 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01967368 Comparator | Oct 2013 → May 2014 | influenza | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT01368796 Comparator | Jul → Dec 2011 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01215669 Comparator | Oct 2010 → Feb 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| — | NCT00760175 Comparator | Oct 2008 → Dec 2009 | influenza | University of Alberta | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaxigrip | “Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern...” NCT02957890 ↗27“1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)” NCT01249183 ↗ “To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28” NCT03266237 ↗ “The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.” NCT00758212 ↗ “standard trivalent intramuscular (IM) vaccine (Vaxigrip® 15 μg, Sanofi Pasteur)” PMID 25483667 ↗ 2014 “Injection of the conventional flu vaccine: Vaxigrip to all study participants.” NCT01010737 ↗ “Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine.” NCT03016143 ↗ “MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)” NCT01022749 ↗ “Vaxigrip” NCT01119157 ↗ |
| Known as | Vaxigrip 2009/2010 | “Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently” NCT01000584 ↗ |
| Known as | VAXIGRIP Prefilled Syringe INJ. | “VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL” NCT02263131 ↗ |
| Modality | Vaccine | “trivalent inactivated influenza vaccine” NCT00386542 ↗ |
| Route | Other | “given intra-dermally” NCT00758212 ↗ |